Dr. Tasian and his research team use an epidemiologic framework, including randomized trials and multi-institutional observational studies, to examine the etiology of kidney stone disease and the comparative effectiveness of surgical interventions. He also employs machine learning of complex data to improve diagnosis, risk stratification, and prediction of treatment response for children and adults with benign urologic disease.
Every week is full of discovery at The Children’s Hospital of Philadelphia. Among the highlights this week are a significant discovery and new treatment option in a heart surgery complication that affects young patients; a study of how to predict infants’ later obesity risk; and a CHOP cancer immunotherapy story hitting the world stage at an international conference.
It’s often surprising for parents to learn that their child has a kidney stone, a painful condition that is more common in adults but has dramatically increased in prevalence among pediatric patients over the last 25 years. Seeing this trend firsthand as a pediatric urologist and epidemiologist at The Children’s Hospital of Philadelphia, Gregory E. Tasian, MD, MSc, MSCE, realized that more research about pediatric kidney stone disease was desperately needed.